LENALIDOMIDE vs SARCLISA ESCENA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 5, 2026·How we rate

Possible drug interaction. LENALIDOMIDE and SARCLISA ESCENA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LENALIDOMIDE	SARCLISA ESCENA
Rating	70/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	LENALIDOMIDE	ISATUXIMAB-IRFC
Manufacturer	Cipla	Sanofi-Aventis U.S. LLC
Dosage forms	Capsule	Injectable
Drug class	Thalidomide Analog	—
Boxed warning	Boxed warning	None
Half-life	about 3 hours in healthy subjects, and 3 to 5 hours in patients with multiple myeloma, MDS, or mantle cell lymphoma	—
Treats	Multiple Myeloma, Myelodysplastic Syndromes, Mantle-Cell Lymphoma	Multiple Myeloma

lenalidomide sarclisa escena

Rating

70/100

72/100

Pharmacy pays

—

Type

Active ingredient

LENALIDOMIDE

ISATUXIMAB-IRFC

Manufacturer

Cipla

Sanofi-Aventis U.S. LLC

Dosage forms

Capsule

Injectable

Drug class

Thalidomide Analog

—

Boxed warning

None

Half-life

about 3 hours in healthy subjects, and 3 to 5 hours in patients with multiple myeloma, MDS, or mantle cell lymphoma

—

Treats

Multiple Myeloma, Myelodysplastic Syndromes, Mantle-Cell Lymphoma

Multiple Myeloma

Frequently asked questions

Which is better-rated, Lenalidomide or Sarclisa Escena?

By our independent rating, Sarclisa Escena scores higher — 3.6 vs 3.5 out of 5 for Lenalidomide. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Lenalidomide and Sarclisa Escena?

Lenalidomide contains Lenalidomide, while Sarclisa Escena contains Isatuximab-Irfc — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.